A0A6D2VYN1 (A0A6D2VYN1_PANTR) Pan troglodytes (Chimpanzee)
T-complex protein 1 subunit alpha UniProtKBInterProInteractive Modelling
556 aa; Sequence (Fasta) ;
3 identical sequences: Homo sapiens: P17987; Pan troglodytes: G2HIL6; Gorilla gorilla gorilla: G3RDV8
Available Structures
49 Experimental Structures
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
cryo-EM structure of human TRiC-ADP-AlFx |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC-tubulin-S3 |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
cryo-EM structure of human TRiC-ATP-closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | ||||
CCT G beta 5 complex closed state 15 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 14 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 0 |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 7 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex close state 11 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 12 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 2 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 6 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 13 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 4 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 9 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 1 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 10 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 3 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex best PhLP1 class |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 8 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 5 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P63261; P78371; Q99832; Q9H2J4; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC complex in closed state with nanobody and tubulin bound |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q13885; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate I |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
The beta-tubulin folding intermediate IV |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
The beta-tubulin folding intermediate II |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 8×AF3; 8×MG; 8×ADP; | |||
The beta-tubulin folding intermediate III |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
hTRiC-hPFD Class3 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class6 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class5 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class1 (No PFD) |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | ||||
hTRiC-hPFD Class4 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class2 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
Human TRiC-PhLP2A-actin complex in the closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P60709; P78371; Q99832; Q9H2J4; | 100 | ||||
Human TRiC complex in closed state with nanobody bound (Consensus Map) |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC/CCT complex with reovirus outer capsid protein sigma-3 |
Heteromer P03527; P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 1×ZN; | |||
Human TRiC in ATP/AlFx closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | ||||
Human TRiC-PhLP2A complex in the closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; Q9H2J4; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Cryo-EM structure of Human TRiC-ATP-open state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | ||||
Cryo-EM structure of human TRiC-NPP state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | ||||
Human TRiC open state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100.0 | 6×ADP; | |||
Cryo-EM structure of human TRiC-tubulin-S2 |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ATP; | |||
cryo-EM structure of human TRiC-ADP |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; | |||
Human TRiC-PhLP2A complex in the open state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; Q9H2J4; | 100 | 10×ADP; | |||
Cryo-EM structure of human TRiC-tubulin-S1 state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100 | 6×ADP; | |||
CCT G beta 5 complex intermediate state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100.0 | 16×ADP; | |||
Human CCT:mLST8 complex |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100.0 | 2×ADP; | |||
Open state CCT-G beta 5 complex |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100.0 | 16×ADP; | |||
Human TRiC complex in open state with nanobody bound |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P78371; Q99832; | 100.0 | 16×MG; 16×ADP; 12×AF3; | |||
Prefoldin-tubulin-TRiC complex |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | 4×ADP; | |||
1 SWISS-MODEL model
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7nvm.1.A | monomer | 0.76 | 1×ADP; 1×AF3; | 100.00 | ||